Get the Stockscreener App
3.90
4.28%
0.16
After Hours:
3.90
Absci Corp stock is traded at $3.90, with a volume of 2.86M.
It is up +4.28% in the last 24 hours and up +8.94% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
See More
Previous Close:
$3.74
Open:
$3.745
24h Volume:
2.86M
Relative Volume:
0.59
Market Cap:
$586.45M
Revenue:
$4.21M
Net Income/Loss:
$-97.67M
P/E Ratio:
-4.1935
EPS:
-0.93
Net Cash Flow:
$-70.76M
1W Performance:
+11.75%
1M Performance:
+8.94%
6M Performance:
+40.79%
1Y Performance:
+15.73%
1-Day Range:
$3.6601
$3.90
1-Week Range:
$3.42
$3.90
52-Week Range:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.90 | 562.39M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Absci Corporation (NASDAQ:ABSI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Absci Unveils Preclinical Data for AI-Designed ABS-201, Targeting a Novel Hormonal Pathway for Hair Loss Treatment - Finviz
Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial - Finviz
Morgan Stanley Assumes Coverage on Absci Corporation (ABSI) with $7 Target - MSN
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Absci Corporation (ABSI) Draws Full Buy Consensus With 150% Upside Potential - Finviz
Absci (NASDAQ:ABSI) Trading Down 4.2%Here's What Happened - MarketBeat
Absci (NASDAQ:ABSI) Trading Up 11.1%Time to Buy? - MarketBeat
Why analysts remain bullish on Absci Corporation stockWeekly Profit Analysis & Smart Investment Allocation Tips - Улправда
Will Absci Corporation stock recover faster than peersMarket Risk Summary & Reliable Entry Point Alerts - Улправда
What technical charts say about Absci Corporation stock2025 Pullback Review & Weekly Chart Analysis and Trade Guides - Улправда
Is Absci Corporation stock a defensive play in 2025CPI Data & Risk Controlled Stock Pick Alerts - Улправда
Will Absci Corporation stock keep outperforming rivalsPortfolio Update Summary & Weekly Sector Rotation Insights - Улправда
How resilient is Absci Corporation stock in market downturns2025 Retail Activity & Step-by-Step Trade Execution Guides - Улправда
ABSI Stock: HC Wainwright & Co. Raises Price Target to $8.00 | A - GuruFocus
Absci Corporation (NASDAQ:ABSI)’s ABS‑201 Shows Promise in Hair Loss Treatment, Analysts See Upside - Insider Monkey
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $8 - 富途牛牛
14 Best Multibagger Penny Stocks to Buy Right Now - Insider Monkey
Will ABS-201 From Absci Transform The Future Of Hair Regeneration? - RTTNews
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Absci (NASDAQ:ABSI) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci’s ABS-201 stimulates human hair follicle growth ex vivo - BioWorld MedTech
Independent Director of Absci Picks Up 454% More Stock - Yahoo Finance
Absci, former US soccer player Donovan announce partnership - MSN
Absci’s ABS-201 antibody shows promise for hair regrowth treatment - Investing.com
Absci’s ABS-201 antibody shows promise for hair regrowth treatment By Investing.com - Investing.com Canada
Absci Reports New Human Ex Vivo Data Demonstrating That - GlobeNewswire
Is Absci Poised for a Surge? - StocksToTrade
Absci (NASDAQ:ABSI) Shares Gap UpShould You Buy? - MarketBeat
Absci, former U.S. soccer player Donovan announce partnership - TipRanks
Absci Corporation Partners with Landon Donovan to Address Androgenetic Alopecia and Advance Therapeutic Innovations - Quiver Quantitative
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewswire
Absci (NASDAQ:ABSI) Transforms Biotechnology With AI Integration - Kalkine Media
Absci Corp Director Frans Van Houten Acquires 40,000 Shares - TradingView — Track All Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Dir Van Houten Buys 40,000 ($148.8K) Of AbSci Corp [ABSI] - TradingView — Track All Markets
Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine? - simplywall.st
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - The Globe and Mail
Absci (NASDAQ:ABSI) Stock Price Up 10.8%Still a Buy? - MarketBeat
Absci doses first volunteers in phase 1/2a trial of hair loss antibody - Investing.com Nigeria
Absci doses first volunteers in phase 1/2a trial of hair loss antibody By Investing.com - Investing.com South Africa
Absci Stock’s Financial Prospects: An In-Depth Analysis - StocksToTrade
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial - simplywall.st
Absci Corp. Strives for New Horizons Amid Financial Adjustments - timothysykes.com
Absci announces first participants dosed in Phase 1/2a HEADLINE trial - TipRanks
Absci (ABSI): Assessing Valuation as AI‑Designed Hair Loss Drug Enters First Phase 1/2a Trial - Yahoo Finance
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Absci Corp Stock (ABSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):